Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform

Shots:

• Finch and Takeda will leverage Finch’s platform to develop microbiome-based therapeutics targeting Crohn’s disease. Takeda to get exclusive worldwide rights to commercialize rationally selected microbiota (RSM) therapies developed for Crohn’s disease
• In 2107, Takeda and Finch collaborated to jointly develop FIN-524 for ulcerative colitis under which Finch has received $10M upfront, milestones & royalties on global sales while Takeda got exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in IBD
• Finch’s human-first discovery platform allows the development of full-spectrum microbiota (FSM) therapies comprising a diverse community of microbiota from human donors as well as RSM therapies containing select bacterial strains, grown in pure culture in human microbiota transplantation studies

Click here to­ read full press release/ article | Ref: Businesswire | Image: Hines